Company: BLCO
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001860742-25-000004
Chunk: 374

Company: Bausch & Lomb Corp
Filing Date: 2025-02-19
Form: 10-K
Item: Item 1A
Chunk 374
---
(3,609)1,886 Acquired in-process research and development intangible assetN/A100 — 100 5 — 5 B&L TrademarkN/A1,698 — 1,698 1,698 — 1,698 $7,345 $(3,851)$3,494 $7,198 $(3,609)$3,589 Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Other expense, net in the Consolidated Statements of Operations. Bausch + Lomb continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present.Asset impairments for 2024, 2023 and 2022 were $5 million, less than $1 million and $1 million, respectively, related to the discontinuance of certain product lines. Estimated amortization expense of finite-lived intangible assets for the five years ending December 31 and thereafter are as follows:(in millions)20252026202720282029ThereafterTotalAmortization$249 $219 $217 $216 $214 $581 $1,696 

F-33

GoodwillThe changes in the carrying amounts of goodwill during the years ended 2024, 2023 and 2022 were as follows:(in millions)Vision CarePharmaceuticalsSurgicalTotalBalance, January 1, 2022$3,596 $675 $315 $4,586 Acquisitions (Note 4)— — 5 5 Foreign exchange and other(47)(30)(7)(84)Balance, December 31, 20223,549 645 313 4,507 Acquisitions (Note 4)— 23 8 31 Foreign exchange and other7 25 5 37 Balance, December 31, 20233,556 693 326 4,575 Acquisitions (Note 4)— — 29 29 Foreign exchange and other(27)(49)(5)(81)Balance, December 31, 2024$3,529 $644 $350 $4,523 Goodwill is not amortized but is tested for impairment at